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Abstract
Introduction: Studying cancer tumors’ microenvironment may reveal a novel role in driving cancer progression
and metastasis. The biological interaction between stromal (mesenchymal) stem cells (MSCs) and cancer cells
remains incompletely understood. Herein, we investigated the effects of tumor cells’ secreted factors as represented
by a panel of human cancer cell lines (breast (MCF7 and MDA-MB-231); prostate (PC-3); lung (NCI-H522); colon
(HT-29) and head & neck (FaDu)) on the biological characteristics of MSCs.
Methods: Morphological changes were assessed using fluorescence microscopy. Changes in gene expression were
assessed using Agilent microarray and qRT-PCR. GeneSpring 12.1 and DAVID tools were used for bioinformatic and
signaling pathway analyses. Cell migration was assessed using a transwell migration system. SB-431542, PF-573228
and PD98059 were used to inhibit transforming growth factor β (TGFβ), focal adhesion kinase (FAK), and mitogen
activated protein kinase kinase (MAPKK) pathways, respectively. Interleukin-1β (IL1β) was measured using ELISA.
Results: MSCs exposed to secreted factors present in conditioned media (CM) from FaDu, MDA-MB-231, PC-3 and
NCI-H522, but not from MCF7 and HT-29, developed an elongated, spindle-shaped morphology with bipolar
processes. In association with phenotypic changes, genome-wide gene expression and bioinformatics analysis
revealed an enhanced pro-inflammatory response of those MSCs. Pharmacological inhibitions of FAK and MAPKK
severely impaired the pro-inflammatory response of MSCs to tumor CM (approximately 80% to 99%, and 55% to
88% inhibition, respectively), while inhibition of the TGFβ pathway was found to promote the pro-inflammatory
response (approximately 3-fold increase). In addition, bioinformatics and pathway analysis of gene expression data
from tumor cell lines combined with experimental validation revealed tumor-derived IL1β as one mediator of the
pro-inflammatory phenotype observed in MSCs exposed to tumor CM.
MSCs exhibited significant tropism toward secreted factors from the aforementioned tumor cell lines, while both
normal and MSCs exposed to tumor CM were capable of attracting human peripheral blood mononuclear cells
(PBMCs).
Conclusions: Our data revealed tumor-derived IL1β as one mediator of the pro-inflammatory response in MSCs
exposed to tumor CM, which was found to be positively regulated by FAK and MAPK signaling and negatively
regulated by TGFβ signaling. Thus, our data support a model where MSCs could promote cancer progression
through becoming pro-inflammatory cells within the cancer stroma.
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Introduction
Stromal (mesenchymal) stem cells (MSCs), also referred
to as stromal cells, are multipotent cells which are present
within the stroma of bone marrow and probably other
organs and capable of differentiating into the three canon-
ical lineages: osteoblasts, adipocytes and chondrocytes [1].
Aside from their differentiation potential, MSCs are also
capable of migrating to injured tissues and contributing
to tissue regeneration [2-4]. Emerging data suggest that
MSCs possess immunomodulatory and regenerative prop-
erties as they can secrete a large number of growth factors
and immune active molecules [5] that can improve tissue
survival and suppress the activity of various immune cells,
such as alloantigen activated T and B lymphocytes [6,7].
Moreover, MSCs can secrete a large number of paracrine
factors, including chemoattractants for endothelial cells,
monocytes and macrophages [8]. Several recent studies
have reported that bone marrow MSCs migrate to the
stromal compartment of tumors [9,10] and that a dynamic
interaction between tumor cells and MSCs exists resem-
bling what has been reported during inflammation and,
thus, ‘tumors are wounds that never heal’ [11].
Over the past several years, a significant amount of
research has emerged documenting a role for MSCs in
promoting epithelial-to-mesenchymal transition (ETM) and
accelerating tumor growth and metastasis [9,12-14]. In
addition, MSCs are being introduced into therapy for a
number of clinical indications and there is a concern of
possible promoting effects on tumor growth by MSCs
[15]. On the other hand, several other studies reported that
MSCs exert tumor suppressive effects [16-18]. Therefore,
understanding the settings under which MSCs exert
promoting versus inhibitory effects on tumor growth and
metastasis is currently under intensive investigation.
Given this complex interplay between MSCs and tumor
cells, the goal of this study was to assess the cellular and
molecular changes in MSCs in response to secreted factors
present in conditioned media (CM) from a panel of human
tumor cell lines covering a spectrum of human cancers
(breast, prostate, lung, colon, and head and neck). Inte-
grated analysis of phenotypic changes, gene expression
and bioinformatics revealed a pro-inflammatory re-
sponse of MSCs when exposed to CM of several tumor
cell lines. Interestingly, the biological responses of
MSCs were not identical. MSCs responded mainly to
tumor cell lines which express high levels of IL1β. We
identified tumor-derived IL1β as the prominent cyto-
kine responsible for induction of inflammatory response
in MSCs and signaling via focal adhesion kinase (FAK)
and, to lesser extent, mitogen activated protein kinase
kinase (MAPKK), as key positive regulators of an in-
flammatory response, while transforming growth factor
β (TGFβ) signaling was found to inhibit the response of
MSCs to tumor CM. Our data further support a model
where MSCs could drive tumorigenicity through induction
of inflammation.
Methods
Ethics statement
Experiments performed in this study do not need ethics
committee approval.
Cell culture
Tumor cell lines used in this study (breast, MCF7 and
MDA-MB-231; prostate, PC-3; lung, NCI-H522; head
and neck, FaDu; and colon, HT-29) have been described
previously [19-23]. The human telomerized hMSC-TERT-
GFP cell line was developed by Dr Kassem, Odense,
Denmark [24,25]. All cell lines were maintained in (D)MEM
4.5g/L glucose (Invitrogen Corp., Carlsbad, CA, USA) and
supplemented with 10% fetal bovine serum, 1% NEAA, 1%
L-glutamine, 100 mg/L penicillin and 100 mg/L strepto-
mycin at 37°C and 5% CO2. For TGFβ inhibition experi-
ments, MSC were cultured as described above and
were exposed to MDA-MB-231 CM in the presence of
10 μM SB-431542 (Sigma, St. Louis, MO, USA). Control
wells were treated with dimethyl sulfoxide (DMSO). CM
plus SB-431542 or vehicle (DMSO, Sigma) was changed
every three to four days for the duration of the experiment.
Recombinant human IL1β and IL6 were purchased from
Invitrogen. FAK inhibitor (PF-573228) and mitogen activated
protein kinase kinase (MAPKK) inhibitor (PD98059) were
purchase from Sigma and were reconstituted in DMSO.
Collection of tumor cell lines conditioned media
The tumor cell lines, MCF7, HT-29, MDA-MB-231, PC-3,
NCI-H522 and FaDu were seeded in six-well plates at
1 × 106/well (4 ml total) in (D)MEM supplemented with
10% fetal bovine serum (FBS), 1% NEAA and 1% penicillin/
streptomycin and incubated at 37°C and 5% CO2. Forty-
eight hours later (cells were approximately 90% confluent),
CM from the tumor cell lines were collected and spun
down at 300 × g for 10 minutes to remove any cellular
content and debris. In some experiments, CM was passed
through a 0.45 μM filter to remove any remaining cellular
content and debris. The hMSC-TERT-GFP cells were then
seeded in 24-well plates at 8 × 104/ml in the collected CM
(80% tumor CM + 20% fresh medium). The MSCs were
exposed to fresh CM every two to three days for the
duration of the experiment.
Quantification of secreted IL1β using ELISA
Quantification of secreted IL1β from tumor cell lines or
from MSCs exposed to tumor CM was done using the
LEGEND MAX™ Human IL-1β ELISA Kit (Biolegened
Inc., San Diego, CA, USA) according to the manufacturer’s
recommendations. CM from tumor cell lines were collected
as described above and stored at −80°C for the ELISA. To
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measure secreted IL1β from control MSCs or MSCs
exposed to tumor CM, MSCs were exposed to MCF7
or FaDu CM for seven days. Subsequently, the cells
were washed three times with PBS and fresh culture
medium was added. CM was collected for the ELISA
72 hours later.
Fluorescence microscopy
Microscopy was performed on the indicated days using
a Nikon® ECLIPSE Ti-U inverted fluorescence micro-
scope. Cells were either imaged directly or were washed
with 1x PBS, followed by staining with Hoechst 33342
(10 μg/ml) in PBS for 10 minutes at 37°C.
Microarray experiment
Human MSCs were exposed to FaDu tumor CM as
described above. On day 7, when the spindle-shape
phenotype was usually observed, the cells from three differ-
ent replicates were harvested and RNA was extracted using
the Roche MagNA Pure automated nucleic acid purification
system (Roche Diagnostics GmbH, Mannheim, Germany).
RNA quantity and quality were measured using the
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). Control RNA was collected from
the same batch of MSCs exposed to normal medium.
Extracted RNA was labeled and then hybridized to the
Agilent Human GE 4x44K v2 Microarray chip (Agilent
Technologies, Santa Carla, CA, USA). All microarray ex-
periments were conducted at the Microarray Core Facility
(Stem Cell Unit, King Saud University College of Medicine,
Riyadh, Saudi Arabia). Data analyses were conducted using
GeneSpring X software (Agilent Technologies) and the
DAVID bioinformatic tool as described previously [26].
Microarray data were deposited in the Gene Expression
Omnibus (GEO) database (accession number GSE50722).
Quantitative real-time polymerase chain reaction
The expression of a panel of genes identified from the
microarray experiment in MSCs exposed to tumor CM
from FaDu, MCF7, MDA-MB-231, PC-3 and NCI-H522
was performed using the StepOne Plus PCR system
(Applied Biosystems Inc, Foster City, CA, USA); the
primers used are listed in Table 1. Briefly, RNA was
extracted using the Roche MagNA Pure automated nucleic
acid purification system (Roche Diagnostics GmbH).
cDNA was generated using a High-Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems Inc). The
real-time PCR reaction was run using Fast SYBR®
Green Master Mix (Applied Biosystems Inc). The rela-
tive fold change in RNA expression was calculated
using the 2−ΔΔCt method, where the average of ΔCt
values for the amplicon of interest were normalized to
that of an endogenous gene (GAPDH), compared with
control specimens [27].
Table 1 Primer sequences used for qRT-PCR
No. Name Sequence
1 CCL3
F 5’ AAGGACACGGGCAGCAGACA 3’
R 5’ AGCAGCAAGTGATGCAGAGAACTGG 3’
2 CCL5
F 5’ TACATTGCCCGCCCACTGCC 3’
R 5’ TCGGGTGACAAAGACGACTGCT 3’
3 CCL8
F 5’ GGGACTTGCTCAGCCAGATTCAGT 3’
R 5’ CAGCACAGACCTCCTTGCCCC 3’
4 CXCL2
F 5’ GGGGTTCGCCGTTCTCGGA 3’
R 5’ TGCGAGGAGGAGAGCTGGCAA 3’
5 CXCL3
F 5’ CGCCCAAACCGAAGTCATAGCCA 3’
R 5’ TGGTAAGGGCAGGGACCACCC 3’
6 CXCL5
F 5’ GTTGAGAGAGCTGCGTTGCGT 3’
R 5’ TCAGGGAGGCTACCACTTCCACC 3’
7 CXCL6
F 5’ GGTAAACTGCAGGTGTTCCCCGC 3’
R 5’ CCCGTTCTTCAGGGAGGCTACCA 3’
8 IL6
F 5’ CGAGCCCACCGGGAACGAAA 3’
R 5’ GGACCGAAGGCGCTTGTGGAG 3’
9 IL1B
F 5’ AGGCACAAGGCACAACAGGCT 3’
R 5’ TGGCTGCTTCAGACACTTGAGCAAT 3’
10 IGF2
F 5’ GCTCTGCCCCGTCGCACATT 3’
R 5’ TTGGTGTCTGGAAGCCGGCGA 3’
11 EHF
F 5’ GGCATGGGGTTGCCGGAGAG 3’
R 5’ CTGGAAACATTGCACGTGGAGTAGC 3’
12 CSF2
F 5’ GACCTCCAGGAGCCGACCTGC 3’
R 5’ AGTTTCCGGGGTTGGAGGGCA 3’
13 SAA1
F 5’ GGCTTTTGATGGGGCTCGGGA 3’
R 5’ CCCCCAGGTCCCCTTTTGGC 3’
14 MMP12
F 5’ TGCCCGTGGAGCTCATGGAGAC 3’
R 5’ TGTGCATCCCCTCCAATGCCAG 3’
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In vitro angiogenesis assay
An in vitro angiogenesis assay was conducted as we de-
scribed previously [28]. MSCs were seeded in a 24-well
plate at 8 × 104/well in normal or CM from FaDu or MDA-
MB-231 cell lines. On day 10, a 24-well plate was prepared
for the matrigel assay by adding 250 μl of chilled Matrigel®
(10 mg/mL, Basement Membrane Matrix, BD Biosciences,
San Diego, CA, USA) for each well, and then the plate was
incubated at 37°C for 30 minutes. MSCs exposed to CM or
control were trypsinized and cultured in 24-well plates pre-
coated with Matrigel® at 1 × 105 in 500 μl of media. Images
were taken at 2 hours and 72 hours using a Nikon®
ECLIPSE Ti-U inverted fluorescence microscope.
Adipogenic and osteoblastic differentiation
MSCs were seeded in a 24-well plate at 8 × 104/well in
normal or CM from FaDu or MDA-MB-231 cell lines.
On day 10, cells were switched to adipogenic ((D)MEM
supplemented with 10% FBS, 10% horse serum (Sigma), 1%
penicillin/streptomycin, 100 nM dexamethasone, 0.45 mM
isobutyl methyl xanthine ((IBMX) (Sigma)), 3 μg/mL
insulin (Sigma) and 1 μM rosiglitazone ((BRL49653)
(Novo Nordisk, Bagsvaerd, Denmark)) or osteogenic ((D)
MEM containing 10% FBS, 1% penicillin/streptomycin,
50 μg/mL L-ascorbic acid (Wako Chemicals GmbH,
Neuss, Germany), 10 mM β-glycerophosphate (Sigma), and
10 nM calcitriol ((1α,25-dihydroxy vitamin D3) (Sigma)),
10 nM dexamethasone (Sigma)) differentiation medium
as we previously described [28]. Medium was changed
every three days. On day 6, adipocytic and osteoblastic
differentiation was measured using Oil-Red-O and alkaline
phosphatase (ALP) staining, respectively.
Transwell cell migration assay
On the day of the experiment, tumor cells were trypsinized
and counted using an automated cell counter (Vi-Cell XR
cell viability analyzer, Beckman Coulter Inc, Fullerton, CA,
USA). Subsequently, 4 × 105 cells were seeded in 2 ml of
low serum (D)MEM ((D)MEM + 1% FBS, 1% NEAA, 1%
penicillin/streptomycin) in the lower chamber of a 12-well
transwell migration system (BD Biosciences). Twenty four
hours later, 1 × 105 hMSC were re-suspended in 1 ml of
low serum (D)MEM in the upper chamber. MSC migration
toward (D)MEM supplemented with 1% FBS was used as a
negative control. Twenty four hours later, inserts were
removed, and cells on the upper surface were scraped
using a cotton swap, and, subsequently, were fixed with
4% Paraformaldehyde (PFA) for 20 minutes, followed
by H & E staining. Stained inserts were subsequently
cut and mounted on microscope slides. Digital slides
were taken using a digital microscope and eight (1600 ×
1000 mcM2) fields were counted from each insert. For
leukocyte migration, MSCs were exposed to tumor CM
for seven days. Subsequently, wells were washed and
fresh (D)MEM + 0.5% BSA was added. CM from control
MSCs ((D)MEM + 0.5% BSA) or MSCs exposed to FaDu
CM ((D)MEM + 0.5% BSA) was collected 72 hours later
and used in the migration experiment. Human peripheral
blood mononuclear cells (PBMCs) (1 × 105) were seeded in
the upper chamber, while control medium or MSC CM was
placed in the lower chamber. Two hours later, images of mi-
grating cells were taken using a Zeiss inverted microscope.
Statistical analysis
Statistical analyses and graphing were performed using
Microsoft® excel 2007 and Graphpad Prism 6.0 software
(Graphpad® software, San Diego, CA, USA). P values were
calculated using the two-tailed t-test. Correlative analyses
were done using Pearson’s correlation using Graphpad
prism 6.0.
Results
Effects of conditioned media on MSCs morphology and
gene expression
Initially, we assessed the effect of CM from a FaDu tumor
cell line on MSC morphology. We observed a striking
difference in the shape of MSCs following five to seven
days exposure to FaDu CM compared to control MSC
culture (Figure 1a). MSCs exposed to FaDu CM exhibited a
spindle-shaped morphology and were more elongated with
bipolar processes compared to the larger control MSCs
with flattened morphology.
This striking finding led us to hypothesize that secreted
factors from FaDu tumor cells mediated biological changes
in MSC phenotype and gene expression. To identifiy those
genetic changes, we conducted global gene expression ana-
lysis of MSCs exposed to FaDu CM compared to control
MSCs cultures. Microarray data and pathway analyses of the
upregulated genes revealed significant enrichment for genes
involved in inflammatory response-related cytokines and
chemokines, for example, IL1β, CSF2, CSF3, IL6, CXCL2,
CXCL1, IL13 and IL1α, as well as metalloproteinases
(Figure 1b, c, and Additional file 1: Table S1).
Effects of CM from tumor cell lines on MSC morphology
and gene expression is cell line-dependent
We subsequently sought to determine if secreted factors
from other tumor cell lines exert similar phenotypic and
gene expression changes on MSCs to those seen with
FaDu. MSCs were exposed to CM collected from a panel
of human cancer cell lines (MCF7 and MDA-MB-231
(breast), PC-3 (prostate), NCI-H522 (lung) and HT-29
(colon)). Changes in morphology were evaluated on days
1, 2, and 7. Interestingly, MSCs exposed to all cell lines,
except MCF7 and HT-29 CM, exhibited marked changes
in appearance compared to control cells (Figure 2). MSCs
exposed to PC-3 developed spindle shape morphology,
with bipolar cellular projections at day 7 and MSCs
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exposed to NCI-H522 and MDA-MB-231 CM exhibited
similar morphological changes but were less pronounced.
Interestingly, these morphological changes were absent
in MSC cultures exposed to MCF7 and HT-29 CM.
Nonetheless, the confluency of MSCs was relatively
higher in control, MCF7 and HT-29 CM compared to
that in FaDu, MDA-MB-231, PC-3 and NCI-H522 CM,
suggesting a possible growth inhibitory effect of the
latter CM on MSC growth. In fact, MSCs exposed to
FaDu CM had a relatively slower growth rate compared
to control MSCs, which was also associated with a de-
crease in the G1 and increase in the G2M phase of the
cell cycle [see Additional file 2: Figure S1].
Given our finding that the highest enrichment in
upregulated genes in MSCs exposed to FaDu CM was
in the category of inflammatory cytokines and matrix
metalloproteinases (MMPs) (Figure 1b, c, and Additional
file 1: Table S1 and Additional file 3: Table S2), the ex-
pression of a selected group of genes in MSCs exposed
to FaDu, in addition to the CM from other cancer cell
lines was subsequently validated using qRT-PCR. Over-
all, our data revealed similar expression patterns of the
selected genes in MSCs exposed to FaDu, NCI-H522,
MDA-MB-231 and PC-3 CM, while the expression of
those genes was lower in MSCs exposed to MCF7 CM
(Figure 3a-e). In addition, we found a significant correl-
ation between the expression of these genes in MSCs
exposed to FaDu, MDA-MB-231 and PC-3 CM, but not
in MSCs exposed to MCF7 CM (Figure 3f ). As seen in
Figure 2, the gene expression data correlated with the
Figure 1 Effects of FaDu conditioned medium (CM) on human MSC morphology and gene expression. (a) Representative micrographs of
MSC-GFP cells grown under normal conditions (left panel) or exposed to FaDu CM (right panel). Hoechst 33342 was used for nuclear staining and
images were obtained at the indicated time points (10× magnification, 200 μm scale bar). Arrow heads point to MSCs with fibroblastic
morphology in CM treated cells. (b) MSCs grown under normal conditions or exposed to FaDu CM were subjected to microarray analysis.
Differentially upregulated genes in MSCs exposed to FaDu CM were subsequently subjected to pathway analysis as described in Methods. The
pie chart represents the top ten pathways where the pie size represents percent enrichment of the pathway. (c) Genes in the cytokine and
inflammatory response pathway were among the most highly enriched category in the microarray data. MSCs, mesenchymal stem cells.
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observed phenotypic changes. MSCs exposed to FaDu
CM secreted a significant amount of IL1β, compared to
control MSCs or MSCs exposed to MCF7 CM (Figure 3g),
which is concordant with the qRT-PCR data.
Pro-inflammatory response of MSCs exposed to FaDu CM is
mediated mainly through focal adhesion kinase signaling
Pathway analysis of differentially expressed genes in MSCs
exposed to FaDu CM revealed multiple enriched pathways.
Among those, FAK (P = 2.1 × 10 -5) and, to lesser extent,
MAPK (P = 0.03) were very prominent [see Additional
file 1: Table S1]. Differentially expressed genes in the
FAK pathway are shown in Figure 4a and b. To assess
whether FAK and MAPK pathways are indeed involved
in regulating the pro-inflammatory response of MSCs
exposed to tumor CM, MSCs were exposed to control or
FaDu CM in the presence of PF-573228 (FAK inhibitor),
PD98059 (MAPKK inhibitor) or DMSO. On day 5, cells
were monitored for phenotypic changes. As shown in
Figure 4c, FAK inhibitor almost completely inhibited the
pro-inflammatory phenotype, while MAPKK inhibitor
had a less pronounced effect. qRT-PCR analysis of a
panel of pro-inflammatory cytokines (IL1β, CXCL6, IL6
and CXCL5) revealed drastic inhibition of the expression
of those cytokines in the presence of FAK inhibitor in a
dose dependent manner (Figure 4d). MAPKK inhibitor
also significantly inhibited the pro-inflammatory response
in MSCs exposed to FaDu CM, but less than that seen
with the FAK inhibitor (Figure 4d).
Signaling via TGFβ negatively regulates the pro-inflammatory
response of MSCs to FaDu CM
Given its critical role in tumorigenicity and in regulating
the differentiation of MSCs [29-31], we hypothesized
that changes in TGFβ signaling could potentially regulate
the observed changes in the phenotype of MSCs. Interest-
ingly, pharmacological inhibition of the TGFβ receptor
kinase using SB-431542 (10 μM) in MSCs in the presence
of MDA-MB-231 CM (this cell line was selected because
it has the highest expression of TGFβ among all cell lines
used in this study, data not shown) led to significant
enhancement in the characteristic morphology of MSCs
(Figure 5a). Concordant with that, the expression of the
pro-inflammatory cytokine panel was significantly increased
in the presence of SB-431542 compared to control DMSO
(>3-fold), Figure 5b. On the other hand, treating MSCs with
recombinant TGFβ1 and TGFβ3 in the presence of FaDu
CM (this cell line was selected for this experiment since it
induced the strongest phenotype and has low TGFβ expres-
sion compared to MDA-MB-231) led to significant inhib-
ition of the pro-inflammatory phenotype at the cellular and
molecular levels (Figure 5c and d). Therefore, our data indi-
cate an inhibitory role for TGFβ signaling on mediating the
observed changes in the MSCs phenotype.
MSCs exposed to tumor CM have diminished multilineage
differentiation potential
Recent study using an in vitro angiogenesis assay has
indicated that human MSCs exposed to CM from a
Figure 2 Comparative analysis of morphological changes in MSCs exposed to conditioned medium (CM) from a panel of human
cancer cell lines. MSCs were grown under normal conditions ((D)MEM) or were exposed to CM from the indicated cancer cell lines
(FaDu, MCF7, MDA-MB-231, PC-3, NCI-H522 and HT-29) and, subsequently, images were obtained on days1, 2 and 7. Representative
micrographs from at least three independent experiments are shown. All images were taken using 10x magnification. MSCs,
mesenchymal stem cells.
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glioblastoma cell line form a vascular-like tubular network
[32]. Therefore, MSCs were exposed to CM from two
selected cancer cell lines: FaDu and MDA-MB-231 for
10 days, then cells were seeded on a Matrigel® matrix and
their ability to form a vascular-like tubular network was
assessed during a 72-hour period. Control MSCs began to
align and form tubular network structures as early as two
hours post-cultivation on Matrigel® (Figure 6a, upper left),
a b c
d e f
g
Figure 3 Validation of selected genes in the cytokine, inflammation, and metalloproteases pathways in MSCs exposed to conditioned
medium (CM) from a panel of human cancer cell lines. MSCs were exposed to CM as described in Figure 2, then qRT-PCR was utilized to
validate the expression of selected genes in the cytokine, inflammation, and metalloproteases pathways in MSCs exposed to CM of FaDu (a),
NCI-H522 (b), MDA-MB-231 (c), MCF7 (d) and PC-3 (e). Data are presented as mean fold change (relative to control MSCs) ± S.D. from at least
two independent experiments, n = 4. P values * <0.05, ** <0.005, *** <0.0005. (f) Correlative analysis of the expression of the aforementioned
genes in FaDu versus the other cell lines. (g) Quantification of secreted IL1β by ELISA from MSCs exposed to MCF7 or FaDu CM. Data are
presented as mean ± S.D. n = 3. MSCs, mesenchymal stem cells.
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Figure 4 (See legend on next page.)
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Figure 4 Inhibition of FAK and MAPK abrogates the pro-inflammatory response in MSCs exposed to FaDU CM. (a) The focal adhesion
kinase (FAK) pathway was among the top upregulated pathways in MSCs exposed to FaDu CM. (b) The list of differentially expressed genes in the FAK
pathway in MSCs exposed to FaDu CM. (c) Pharmacological inhibition of FAK (5 μM, PF-573228, Sigma) or MAPKK (5 μM, PD98059, Sigma) led to
significant inhibition of the pro-inflammatory response in MSCs exposed to FaDu CM. (d) Quantification of a representative set of genes in the
cytokine and inflammatory response pathway in MSCs exposed to FaDu CM in the presence of DMSO, FAK, or MAPKK inhibitors. Data are presented as
percent change in gene expression relative to MSCs exposed to FaDu CM + DMSO. Data are presented as mean ± S.D. n = 3. CM, conditioned media;
DMSO, dimethyl sulfoxide, FAK, focal adhesion kinase; MAPKK, mitogen activated protein kinase kinase; MSCs, mesenchymal stem cells.
c d
ba
Figure 5 TGFβ signaling negatively regulates the pro-inflammatory response of MSCs exposed to tumor CM. (a) MSCs were cultured as
described in Methods and then were exposed to MDA-MB-231 CM in the presence of 10 μM SB-431542 or DMSO. On the indicated days, nuclei
were stained with Hoechst 33342 and cells were visualized under a florescent microscope. Data are representative of at least three independent
experiments. (b) Quantification of a representative set of genes in the cytokine and inflammatory response pathway in MSCs exposed to
MDA-MB-231 CM in the presence of 10 μM SB-431542 or DMSO from a. Data are presented as the fold change in gene expression relative to control
MSCs. Data are presented as mean ± S.D. n = 3. (c) MSCs were cultured as described in Methods and then were exposed to FaDu CM in the presence
of 10 μg/ml TGFβ1 and TGFβ3. On Day 5, cells were visualized under a florescent microscope (4x). (d) Quantification of a representative set of genes in
the cytokine and inflammatory response pathway in MSCs exposed to FaDu CM in the presence of 10 μg/ml TGFβ1 and TGFβ3 from c. Data are
presented as percent change in gene expression relative to MSCs exposed to FaDu CM + vehicle (dH2O). Data are presented as mean ± S.D. n = 3.
CM, conditioned media; DMSO, dimethyl sulfoxide; MSCs, mesenchymal stem cells.
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which was very noticeable by 72 hours (Figure 6a, middle
and bottom left). MSCs exposed to FaDu and MDA-MB-
231 CM failed to form any tubular structures up to 72 hours
(Figure 6a, middle and right panels). Similarly, MSCs
exposed to FaDu or MDA-MB-231 CM had dimin-
ished adipogenic and osteogenic differentiation potential
(Figure 6b and c). Interestingly, the inhibitory effect was
more evident in MSCs exposed to FaDu CM compared
to MDA-MB-231 CM, which seems to correlate with
the induction of a pro-inflammatory response in MSCs
(compare Figure 6b, c, and Figure 3a, c). Taken together,
these data suggest that exposing MSCs to FaDu or MDA-
MB-231 CM induced the differentiation of MSCs into
pro-inflammatory cells, which was also associated with
diminished multilineage differentiation potential.
Clustering analysis of tumor cell lines gene expression profile
We subsequently determined if the changes in MSCs
phenotype and gene expression pattern post exposure to
tumor CM are associated with the genetic characteristics of
the tumor cell lines employed. Thus, publicly available gene
expression data for FaDu, MCF7, HT-29, MDA-MB-231,
NCI-H522 and PC-3 were retrieved from The Gene
Expression Omnibus ([33]; Series Accession GSE36133)
and were subjected to bioinformatics. Since the pro-
inflammatory phenotype was most evident in MSCs
exposed to FaDu and PC-3 CM, while it was absent in
MSCs exposed to MCF7 or HT-29 CM, we performed
clustering analyses on the significantly differentially
expressed genes in FaDu and PC-3, compared to MCF7
and HT-29 cell lines using GeneSpring X software.
Data presented in Figure 7a revealed close clustering
of the FaDu and PC-3, followed by MDA-MB-231 and
NCI-H522, while MCF7 and HT-29 exhibited poor
clustering with the above mentioned cell lines. Inter-
estingly, the cytokine and inflammatory response was
among the top upregulated pathways in the differen-
tially expressed genes in FaDu and PC-3, compared to
MCF7 and HT-29 (Figure 7b and c). IL1β was the most
highly upregulated gene in FaDu and PC-3 compared
to MCF7 and HT-29 (Figure 7c, and d). Concordant
with that, FaDu and PC-3 secreted the largest amount
of IL1β, followed by MDA-MB-231 and NCI-H522,
while HT-29 and MCF7 secreted the smallest amount of
IL1β. Interestingly, IL1β production by tumor cells seemed
to correlate with the induced pro-inflammatory phenotype
(compare Figure 7e and Figure 3).
IL1β treatment induced a pro-inflammatory phenotype in
MSCs similar to that induced by tumor CM
Data presented in Figure 7 suggest that tumor derived
IL1β might be the main cytokine responsible for the
pro-inflammatory response in MSCs exposed to tumor
CM. To test this hypothesis, MSCs were grown in normal
(D)MEM in the presence of IL1β or IL6. Interest-
ingly, treating MSCs with IL1β phenocopied the pro-
inflammatory phenotype seen in MSCs exposed to
tumor CM, while IL6 treatment had almost no effect on
the MSC phenotype (Figure 8a). The effect of IL1β was
dose-dependent [see Additional file 4: Figure S2]. Similarly,
exposing MSCs to IL1β led to significant upregulation of
the pro-inflammatory cytokines (7.5 to 120 fold). On the
other hand, exposing MSCs to IL6 had only slight increase
in IL1β expression (1.4 fold, Figure 8b).
MSCs exhibited significant tropism toward different
tumor cell lines in vitro
To establish a model of a potential crosstalk between
MSCs and tumor cells, we then determined if different
tumor cell lines are chemoattractant to MSCs in vitro.
To that end, we conducted a transwell migration experi-
ment in which different tumor cell lines were seeded in the
lower chamber under low serum conditions, while MSCs
were seeded in the upper chamber. Data presented in
Figure 9a revealed a significant increase in MSC migration
toward all tumor cell lines compared to control media,
thus confirming the potential tropism of MSCs toward
secreted factors from the tumor cells. Although all tumor
cell lines exhibited similar capability to attract MSCs, the
highest migration was seen toward MDA-MB-231 and
PC-3 cell lines (Figure 9b).
Control MSCs or MSCs exposed to tumor CM are capable
of attracting human PBMCs
Previous studies have indicated a role for tumor infil-
trating immune cells in contributing to inflammation,
thus promoting tumorigenicity [34,35]. Therefore, we
investigated whether human MSCs or MSCs exposed to
FaDu CM are capable of attracting human PBMCs. CM
((D)MEM + 0.5% BSA) from MSCs or MSCs exposed to
(See figure on previous page.)
Figure 6 MSCs exposed to tumor CM lose their multipotent differentiation potential. (a) Control MSCs or MSCs exposed to FaDu or
MDA-MB-231 CM (10 days) were harvested and seeded on top of Matrigel® as indicated in Methods sections. Vessel-like tubular formation was
assessed at 2 hours and 72 hours using a fluorescence microscope at 4x and 10x, as indicated. Data are representative of at least two experiments.
Control MSCs or MSCs exposed to FaDu or MDA-MB-231 CM (10 days) were switched to adipogenic (b) or osteogenic induction media (c). On day 6,
adipocyte differentiation was measured using Oil-Red-O staining (b), while osteoblast differentiation was measured using alkaline phosphatase staining
(ALP) (c). Data are representative of at least two experiments. CM, conditioned media; MSCs, mesenchymal stem cells.
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FaDu CM were collected and placed in the lower chamber
in a transwell migration system, while 1 × 105 human
PBMCs were seeded in the upper chamber. As shown in
Figure 10a, a significant increase in PBMC migration to-
ward MSCs or MSCs exposed to FaDu CM was observed.
Discussion
For several decades, the molecular changes within tumor
cells were studied in order to understand factors responsible
for promoting tumor progression and metastasis, while
little attention was paid to the possible contributory role
of tumor microenvironment. Recent evidence suggests
that the tumor microenvironment, which is composed of
a very complex network of extracellular matrix (ECM)
proteins and many cell types, such as endothelial cells,
stromal (mesenchymal) stem cells, pericytes, fibroblasts
and immune cells, plays a critical role in tumor progression
and metastasis [36,37]. Among these components, MSCs
have been the focus of intensive investigation [9,17,38-45].
In the present report, we examined the crosstalk between
tumor cells and MSCs and we investigated the effect(s)
of tumor secreted factors on MSCs at the cellular and
molecular levels. As surrogates for malignant tumors,
we employed a number of well characterized cancer cell
lines. We reported that secreted factors from FaDu cells
led to significant morphological and genetic changes in
MSCs with enhanced expression of pro-inflammatory
cytokines, and similar responses were also observed when
additional tumor cell lines were evaluated. However, these
effects were not universal for all malignant cell lines. For
example, MCF7 and HT-29 did not exert these effects.
Our findings corroborate recent findings of the presence
(See figure on previous page.)
Figure 7 Cluster and pathway analysis of basal gene expression in FaDu, NCI-H522, MDA-MB-231, MCF7, PC-3 and HT-29 tumor cell
lines. (a) Clustering analysis of the tumor cell lines indicated close clustering for FaDu and PC-3, followed by MDA-MB-231 and NCI-H522, while
MCF7 and HT-29 did not cluster readily with the group. Clustering analyses were performed on differentially expressed genes in FaDu and PC-3
relative to MCF7 and HT-29. (b) Cytokine and inflammatory response pathway was among the top enriched pathways in differentially expressed
genes between FaDu and PC-3 relative to MCF7 and HT-29. (c) Genes in the cytokine and inflammatory response pathways from b and their
expression levels are shown. (d) mRNA expression level of IL1β in different tumor cell lines from the microarray data. (e) Quantification of
secreted IL1β by ELISA from different tumor CM. Data are presented as mean ± S.D. n = 3. CM, conditioned media.
b
a
Figure 8 IL1β treatment induced a pro-inflammatory response in MSCs. (a) MSCs were cultured in normal (D)MEM in the presence of
recombinant IL1β (10 and 50 ng/ml), recombinant IL6 (50 ng/ml), both IL1β and IL6 (50 ng/ml each) or in the presence of vehicle control (dH2O).
Images were taken on day 4 and 7 (4x). (b) Quantification of a representative set of genes in the cytokine and inflammatory response pathway in
MSCs exposed to different cytokines from (a). Data are presented as fold change in gene expression relative to MSCs exposed to vehicle. Data
are presented as mean ± S.D., n = 3. MSCs, mesenchymal stem cells.
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of morphological and functional changes in mouse MSCs
in response to cancer cell lines (MDA-MB-231, PANC-1
and U87) CM [46], which exhibit a carcinoma-associated
fibroblast (CAF)-like myofibroblastic phenotype.
Interestingly, several of the pro-inflammatory molecules
identified in the current study have been linked to cancer
progression. For instance, cancer cells that overexpress
CXCL1 and 2 were found to be more primed for survival
at metastatic sites, and are capable of attracting CD11b(+)
Gr1(+) myeloid cells into the tumor that enhance cancer
cell survival and enhance their chemoresistance and
metastatic ability [47]. In addition to that, CXCL2 was
also found to be involved in cancer-associated bone de-
struction [48]. A recent study has reported differentiation
of human MSCs into pericyte–like cells upon exposure
to glioblastoma tumor CM [32]. In our current study,
we observed no evidence of differentiation of MSCs into
pericytes or endothelial-like cells using an in vitro angio-
genesis assay (Figure 6a). In fact, MSCs exposed to FaDu
or MDA-MB-231 CM failed to form any vascular-like
tubular networks compared to control MSCs, suggesting
MSCs have lost their ability to support angiogenesis [49].
a
b
Figure 9 Tumor cells are capable of attracting human MSCs in vitro. Tumor CM ((D)MEM + 1% FBS) was placed in the lower chamber of a
transwell migration system, while MSCs were seeded in the upper chamber. Twenty-four hours later, the number of migrating MSCs was
evaluated. (a) H & E staining of the cells migrating toward CM from the indicated tumor cell lines. Migration toward (D)MEM + 1% FBS was used
as baseline control. (b) Slides were scanned and the number of migrating cells in eight (1,600 x 1,000 mcM2) fields was counted. Data are
presented as mean ± S.D, n = 8. P value * <0.05, ** <0.005, *** <0.0005. CM, conditioned media; MSCs, mesenchymal stem cells.
Al-toub et al. Stem Cell Research & Therapy 2013, 4:114 Page 14 of 18
http://stemcellres.com/content/4/5/114
Nonetheless, MSCs exposed to tumor CM also exhibited
poor adipocytic and osteoblastic differentiation potential
(Figure 6b), probably as a result of differentiation into
pro-inflammatory cells. Glioblastoma are known for their
high angiogenic capability and the secretion of high levels
of VEGF [50], which might account for the variable effects
of CM from breast, lung, prostate, and head and neck
cancer models investigated in the current study compared
to published glioblastoma data [32]; hence, the response
of MSCs to tumor secreted factors can vary depending on
the tumor type.
Our gene expression data revealed significant correlation
between the expression of a panel of genes involved in
inflammation and the metalloprotease pathway (CCL8,
CCL5, CXCL6, CXCL5, SAA1, MMP12, EHF, CCL3,
CSF2, CXCL3, IL6, IGF2, CXCL2 and IL1b) in MSCs
exposed to FaDu and to those exposed to MDA-MB-231,
PC-3 and NCI-522 CM, while the expression of these
genes was almost unchanged in MSCs exposed to MCF7
CM (Figure 3). These data support our hypothesis of the
ability of tumor cells to recruit MSCs to their stroma and
which in turn induce inflammation, either directly or
through recruiting circulating immune cells (Figure 10b).
It seems that this model does not apply to all cancer
models since in the MCF7 model, MSCs seemed to
promote tumorigenicity via direct interaction with tumor
cells (Al-toub et al., in preparation).
Bioinformatics and pathway analysis of gene expression
data from tumor cell lines revealed that the phenotypic
changes were mostly observed in MSCs exposed to
a
b
Figure 10 Both control and MSCs exposed to FaDu conditioned medium (CM) are capable of attracting human PBMCs. (a) Conditioned
medium from MSCs or MSCs exposed to FaDu CM were collected and placed in the lower chamber of a transwell migration system, while
1 x 105 PBMCs were placed in the upper chamber. Representative images of PBMCs migrating to the lower chamber are shown. Data are
representative of at least two independent experiments, conducted in duplicate. (b) A model depicting the crosstalk between tumor cells, MSCs
and immune cells. (1) Tumor cells secrete soluble factors which attract MSCs (2). MSCs at the tumor site become tumor-associated MSCs with
enhanced inflammatory responses and secreted chemokines (3) which attract immune cells (4) to the tumor site, collectively acting to drive
tumorigenicity via enhanced inflammation as one potential mechanism of tumor progression. CM, conditioned media; MSCs, mesenchymal stem
cells; PBMCs, peripheral blood mononuclear cells.
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CM from cell lines with a pro-inflammatory nature
(such as, FaDu and PC-3, Figure 7c). Indeed our investiga-
tion has identified tumor-derived IL1β to be the primary
driver of the pro-inflammatory phenotype observed in
MSCs exposed to tumor CM, whereas treating MSCs with
recombinant IL1β mimicked the effects of tumor CM at
the cellular and molecular level (Figures 7d-e and 8a-b).
Nonetheless, we also identified signaling via FAK and,
to lesser extent, MAPK to be critical for the induction of
the observed phenotype (Figure 4). In contrast, pharma-
cological inhibition of TGFβ signaling in MSCs led to
substantial enhancement in the observed changes in pheno-
type and gene expression in MSCs exposed to MDA-MB-
231 CM (Figure 5a and b), which was also associated with
a slight increase in cell proliferation [see Additional file 5:
Figure S3]. Treating MSCs with recombinant TGFβ1 and
TGFβ3 in the presence of FaDu CM led to significant
inhibition of the observed phenotype at the cellular and
molecular level (Figure 5c and d), which further implicated
TGFβ signaling in negatively regulating MSC differen-
tiation in response to tumor CM. Thus, our findings
corroborate previous studies suggesting a role for the
TGFβ signaling pathway in regulating mesenchymal
stem cell differentiation [31].
Conclusions
Our data support an evolving hypothesis that cancer cells
secrete a large number of factors regulating biological
characteristics of MSCs and transforming MSCs into pro-
inflammatory cells. We identified tumor-derived IL1β as one
potential mediator of the observed phenotype. Nonetheless,
we also identified FAK and MAPK signaling to regulate posi-
tively, while TGFβ signaling was found to negatively regulate
the response of MSCs to tumor CM. Taken together, our
data support a model where MSCs contribute to tumorigen-
icity through their pro-inflammatory phenotype induced by
cancer cell-derived factors, such as IL1β (Figure 10b).
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